Delta-Fly Pharma
Delta-Fly is a small Japanese company from Tokushima that improves existing chemotherapy drugs; its continuous-infusion cytarabine analogue DFP-10917 is in phase 3 for relapsed acute myeloid leukaemia.
Overview
Delta-Fly Pharma, based in Tokushima and listed in Tokyo, develops modified versions of established cytotoxic drugs. Its lead candidate DFP-10917, a deoxycytidine analogue given by continuous infusion, is in a phase 3 trial in relapsed or refractory acute myeloid leukaemia, and DFP-14323, an oral formulation of the protease inhibitor ubenimex, is tested in lung cancer. Its trials are registered on ClinicalTrials.gov under Delta-Fly as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyCyclacel Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyAgennix
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyPeregrine Pharmaceuticals (now Avid Bioservices)
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyTelik
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.